18+ · Research Use Only · Not for Human Consumption
NAD+ decline: the longevity research thesis.
One coenzyme sits under cellular energy, DNA repair and the sirtuin pathways. Its decline with age is the observation the entire NAD+ research field is built on.
Why the pool shrinks
NAD+, nicotinamide adenine dinucleotide, is a redox coenzyme present in every living cell. It shuttles electrons in the reactions that convert food into ATP, which alone would make it central. But it is also a consumable substrate: several enzyme families do not just borrow it, they use it up.
That consumption is where the aging story starts. PARP enzymes draw on NAD+ to run DNA repair, and repair demand climbs as damage accumulates over a lifetime. CD38, an enzyme whose activity is reported to rise with age and inflammation, degrades NAD+ directly. Meanwhile the salvage pathway that recycles the molecule back into circulation becomes less efficient. Falling production against rising consumption is the squeeze, and measured NAD+ decline across aging tissues is one of the more consistent observations in the field.
Sirtuins, PARP and the restoration question
The reason the decline matters, rather than being a curiosity, is what depends on the pool. Sirtuins, the enzyme family most associated with longevity research, are NAD+-dependent: their activity in metabolic regulation, stress response and genomic maintenance is throttled by substrate availability. A shrinking pool also forces triage between competing consumers, with energy metabolism, repair and signaling all drawing from the same account.
The restoration hypothesis follows directly: if decline contributes to aging phenotypes, restoring levels should move something measurable. Animal studies restoring NAD+ report improvements across metabolic, vascular and functional endpoints, and this preclinical body of work is what launched the field. Human trials, mostly with precursors, show levels can be raised. What no one has published is proof of hard longevity outcomes in humans. The thesis remains a thesis, which is exactly what makes it a research field rather than a settled protocol.
Where the research vial fits
Most consumer products approach NAD+ indirectly, through precursors like NMN or NR that feed the salvage pathway. Research protocols frequently work with the molecule itself, which is what the catalogue carries: NAD+ 1000mg vials at ₱2,790, or ₱2,510 on a first order. The precursor-versus-molecule distinction is worked through in the NAD+ vs NMN comparison.
For researchers pairing pathways, the mitochondrial peptide MOTS-c sits one layer away, on signaling rather than substrate, a split covered in MOTS-c vs NAD+. NAD+ stock is held in Metro Manila cold storage, ships same-day across the metro on verified orders before noon, and every vial carries a printed batch number.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
NAD+ research questions
Why does NAD+ decline with age?
Two pressures compound: consumption rises as enzymes like PARPs and CD38 draw down the pool, especially under accumulating cellular stress, while the salvage pathway that recycles NAD+ becomes less efficient. Falling supply meets rising demand.
What are sirtuins and why do they matter here?
Sirtuins are a family of enzymes involved in metabolic regulation, stress response and genomic maintenance. They consume NAD+ to function, which is the direct mechanistic link between the size of the NAD+ pool and the longevity pathways researchers care about.
What does restoration research actually show?
Animal studies restoring NAD+ levels report improvements across metabolic and functional endpoints, and human precursor trials show blood NAD+ can be raised. Hard human longevity outcomes remain unproven. The field is active precisely because that gap is open.
How much is the NAD+ research vial in the Philippines?
Primara Labs stocks NAD+ 1000mg vials at ₱2,790, or ₱2,510 on a first order, from Metro Manila cold storage with same-day metro delivery on verified orders before noon.